RTOG Foundation at ASTRO 2025

The RTOG Foundation Hosts Overview Session Engaging Early Career Investigators at ASTRO

For the first time, the RTOG Foundation hosted an organizational overview session at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Francisco. Held on Monday, September 29th in the Early Career & Mentoring Lounge, the session featured RTOG Foundation Board Members who introduced the organization, highlighted its research initiatives, and shared guidance on how to get involved in clinical trials. The presentation was followed by a networking opportunity and an open Q&A with attendees.

Photo Credit: @djlee714 on X


Press Releases

RadComp Study Health-Related Quality of Life Analysis Shows Benefit in Both Proton and Photon Radiation Options in Breast Cancer Patients

Results from the health-related quality of life (HRQOL) analysis of the University of Pennsylvania and RTOG Foundation RadComp study indicated that both photon and proton radiation treatment options yielded similar, excellent HRQOL outcomes for women with non-metastatic breast cancer. RadComp was the first randomized study comparing proton to photon radiation for breast cancer treatment. These results were recently reported during the Plenary Session of the American Society for Radiation Oncology Annual Meeting in San Francisco, California.

Photo Credit: @drjefstathiou on X


Press Releases out of NRG Oncology



NRG Oncology Trial Results Show Favorable Bowel Health Related Quality of Life Outcomes for Localized Intermediate Risk Prostate Cancer Treated with Stereotactic Body Radiation Therapy

Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate risk prostate cancer indicate that the use of SBRT improved bowel health related quality of life (HRQOL) in this patient population. There was no significant improvement seen for the other primary objectives including urinary HRQOL and there was a lack of improvement in distant-free survival for patients. Read more


Patient-Reported Outcome Analysis of NRG Oncology Trial in Limited-Stage Small Cell Lung Cancer Suggests Quality of Life Benefit with Twice - (vs Once -) Daily Radiation

Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy drug atezolizumab to standard of care concurrent chemoradiation for limited-state small cell lung cancer was reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population. At the same time, an exploratory analysis reported longer median OS among patients who received twice-a-day radiation, though RT schedule was not randomized. As a follow up to that study, a patient-reported outcomes (PRO) analysis explored the impact of the NRG-LU005 treatment regimens on quality of life (QOL).  Read more


NRG Oncology Trial Analysis Shows Improvement in Survival Outcomes for Glioblastoma Patients Receiving Proton Therapy, Trial Moves to Phase III

Previously, results from the photon cohort of NRG-BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not demonstrate improvement in overall survival (OS) for patients with newly diagnosed glioblastoma (GBM). The recent analysis of the proton cohort revealed improved survival for patients receiving proton therapy at 75 Gy. Because this data met the pre-defined survival improvement threshold, they could be used to design and conduct a definitive phase III randomized trial.  Read more



Congratulations, Dr. Le!

Dr. Quynh-Thu Le, Chair of RTOG Foundation, was honored with the 2025 Gold Medal Award from the American Society for Radiation Oncology (ASTRO)—the highest accolade bestowed by the society. This distinguished award recognizes individuals who have made outstanding and enduring contributions to the field of radiation oncology across clinical care, research, education, and professional service.

Photo Credit: @ASTRO_org on X

 
Facebook  X  Instagram  LinkedIn